OrbusNeich Medical wasted no time in enforcing a patent win against Boston Scientific (NYSE:BSX), announcing that it is blocking German imports of its rival’s cardiac stents.
OrbusNeich
German court grants OrbusNeich injunction over Boston Scientific in stents patent row
UPDATED April 30, 2013 with analyst’s reaction; comment from Boston Scientific.
OrbusNeich Medical said a German court granted a preliminary injunction against Boston Scientific (NYSE:BSX) in a legal war over coronary stent patents.
OrbusNeich takes Boston Scientific patent row to Ireland
OrbusNeich continued its global row against medtech titan Boston Scientific (NYSE:BSX) even further, filing a patent infringement lawsuit in Ireland to join ones pending in Germany and the Netherlands.
Legal: OrbusNeich takes Boston Scientific patent row to Germany, the Netherlands
OrbusNeich is taking a recent patent infringement win against Boston Scientific (NYSE:BSX) even further, filing lawsuits in both Germany and the Netherlands to allege patent infringement over stent technology.
UPDATE: OrbusNeich claims European stent patent win over Boston Scientific
UPDATED Feb. 13, 2012 with comment from Boston Scientific.
OrbusNeich claimed a win over Boston Scientific (NYSE:BSX) in a European patent battle over stent technology.
EuroPCR: Sapien win, promising post-approval results weigh in Edwards’ favor
Leerink Swann analysts saw promise in a pair of "tidbits" about Edwards Lifesciences’ (NYSE:EW) Sapien XT transcatheter aortic valve implantation system presented at the EuroPCR conference in Paris this week.
ACC 2012: Stent news from Medtronic, Boston Scientific, OrbusNeich
TCT 2011: Benefits for Edwards’ valve patients increase at the two-year mark
Patients treated with Edwards Lifesciences’ (NYSE:EW) Sapien heart valve had a lower mortality rate and spent less time in hospitals at the two-year mark, according to the data released at this year’s Transcatheter Cardiovascular Therapeutics symposium.
The Partner trial consisted of patients with aortic stenosis, randomized to receive a Sapien valve with transcatheter aortic valve replacement surgery or traditional open-heart surgery.
TCT 2011: Three ways to spur U.S. medical innovation
The U.S. medical device arena is in danger of ceding the throne to countries with friendlier regulatory environments but the system is not irreparable, Dr. Martin Leon said during a lecture at this week’s Transcatheter Cardiovascular Therapeutics symposium in San Francisco.
Stents: Medtronic’s subclavian approach for valve-replacement device achieved “excellent” results in clinical trial | PCR 2011 Roundup
Docs differ on coronary intervention | Research roundup
In early 2009, six medical professional societies got together to write a guide for 180 cardiac revascularization procedures.
A recent survey, however, shows that there may not be consensus amongst the doctors who practice the surgical and percutaneous coronary intervention procedures.